Saccharomyces boulardii CNCM I-745 in different clinical conditions

Expert Opinion on Biological Therapy

Volumn 14, Issue 11, 2014, Pages 1593-1609

  Dinleyici, Ener Cagri ^a   Kara, Ates ^b   Ozen, Metehan ^c   Vandenplas, Yvan ^d  

^a OSMANGAZI UNIVERSITY MEDICAL FACULTY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^d UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Antibiotic associated diarrhea; Diarrhea; Probiotics; Saccharomyces boulardii; Saccharomyces boulardii CNCM I 745

Indexed keywords

ANTIBIOTIC AGENT; CNCM I 745; PROBIOTIC AGENT; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ACUTE DIARRHEA; ACUTE GASTROENTERITIS; ANTIBIOTIC ASSOCIATED DIARRHEA; BACTERIAL CLEARANCE; CHILDHOOD DISEASE; CROHN DISEASE; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE DURATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEEDING; HELICOBACTER PYLORI; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INFECTIOUS DIARRHEA; INFLAMMATORY BOWEL DISEASE; IRRITABLE COLON; LONG TERM CARE; NEWBORN PERIOD; NONHUMAN; REVIEW; SACCHAROMYCES BOULARDII; TRAVELLER DIARRHEA; ULCERATIVE COLITIS; ANIMAL; CHEMICALLY INDUCED; DIET THERAPY; INFLAMMATORY BOWEL DISEASES; PHYSIOLOGY; SACCHAROMYCES;

SACCHAROMYCES BOULARDII;

ANIMALS; ANTI-BACTERIAL AGENTS; DIARRHEA; HUMANS; INFLAMMATORY BOWEL DISEASES; PROBIOTICS; SACCHAROMYCES;

EID: 84911116602     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2014.937419     Document Type: Review

References (72)

1. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 2010;16:2202-22.
2. Czerucka D, Piche T, Rampal P. Review article: yeast as probiotics - Saccharomyces boulardii. Aliment Pharmacol Ther 2007;26:767-78
3. Czerucka D, Rampal P. Experimental effects of Saccharomyces boulardii on diarrheal pathogens. Microbes Infect 2002;4:733-9
4. Buts JP. Twenty-five years of research on Saccharomyces boulardii trophic effects: updates and perspectives. Dig Dis Sci 2009;54:15-18
5. Vandenplas Y, Brunser O, Szajewska H. Saccharomyces boulardii in childhood. Eur J Pediatr 2009;168:253-65
6. Cetina-Sauri G, Sierra Basto G. Therapeutic evaluation of Saccharomyces boulardii in children with acute diarrhea. Ann Pediatr (Paris) 1994;41:397-400
7. Castaneda Guillot C, Garcia Bacallao E, Santa Cruz Dominguez M, et al. Effects of Saccharomyces boulardii in children with chronic diarrhea, especially cases of giardiasis. Rev Mex Pueric Pediatr 1995;2:12
8. Hafeez A, Tariq P, Ali S, et al. The efficacy of Saccharomyces boulardii in the treatment of acute watery diarrhea in children: a multicentre randomized controlled trial. J Coll Physicians Surg Pak 2002;12:432-4
9. Mansour-Ghanaei F, Dehbashi N, Yazdanparast K, Shafaghi A. Efficacy of Saccharomyces boulardii with antibiotics in acute amoebiasis. World J Gastroenterol 2003;9:1832-3
10. Kurugol Z, Koturoglu G. Effects of Saccharomyces boulardii in children with acute diarrhoea. Acta Paediatr 2005;94:44-7
11. Billoo AG, Memon MA, Khaskheli SA, et al. Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea. World J Gastroenterol 2006;12:4557-60
12. Besirbellioglu BA, Ulcay A, Can M, et al. Saccharomyces boulardii and infection due to Giardia lamblia. Scand J Infect Dis 2006;38:479-81
13. Villarruel G, Rubio DM, Lopez F, et al. Saccharomyces boulardii in acute childhood diarrhoea: a randomized, placebo-controlled study. Acta Paediatr 2007;96:538-41
14. Canani RB, Cirillo P, Terrin G, et al. Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ 2007;335:340
15. Vandenplas Y, Badriul H, Thapa B, et al. A multi-centre DBRPC-trial in developing countries with S. boulardii in acute gastroenteritis. J Pediatr Gastroenterol Nutr 2007;44:e86
16. Htwe K, Yee KS, Tin M, Vandenplas Y. Effect of Saccharomyces boulardii in the treatment of acute watery diarrhea in Myanmar children: a randomized controlled study. Am J Trop Med Hyg 2008;78:214-16
17. Dinleyici EC, Eren M, Yargic ZA, et al. Clinical efficacy of Saccharomyces boulardii and metronidazole compared to metronidazole alone in children with acute bloody diarrhea caused by amebiasis: a prospective, randomized, open label study. Am J Trop Med Hyg 2009;80:953-5
18. Savas-Erdeve S, Gokay S, Dallar Y. Efficacy and safety of Saccharomyces boulardii in amebiasis-associated diarrhea in children. Turk J Pediatr 2009;51:220-4
19. Eren M, Dinleyici EC, Vandenplas Y. Clinical efficacy comparison of Saccharomyces boulardii and yogurt fluid in acute non-bloody diarrhea in children: a randomized, controlled, open label study. Am J Trop Med Hyg 2010;82:488-91
20. Grandy G, Medina M, Soria R, et al. Probiotics in the treatment of acute rotavirus diarrhoea. A randomized, double-blind, controlled trial using two different probiotic preparations in Bolivian children. BMC Infect Dis 2010;10:253
21. Correa NB, Penna FJ, Lima FM, et al. Treatment of acute diarrhea with Saccharomyces boulardii in infants. J Pediatr Gastroenterol Nutr 2011;53:497-501
22. Dalgic N, Sancar M, Bayraktar B, et al. Probiotic, zinc and lactose-free formula in children with rotavirus diarrhea: are they effective? Pediatr Int 2011;53:677-82
23. Riaz M, Alam S, Malik A, Ali SM. Efficacy and safety of Saccharomyces boulardii in acute childhood diarrhea: a double blind randomised controlled trial. Indian J Pediatr 2012;79:478-82
24. Dinleyici EC, Eren M, Ozen M, et al. Effectiveness and safety of Saccharomyces boulardii for acute infectious diarrhea. Expert Opin Biol Ther 2012;12:395-410.
25. Dinleyici EC, Eren M, Yargic ZA, Vandenplas Y. Costt-effectiveness of addon probiotics (Saccharomyces boulardii) in children with acute rotavirus diarrhea in Turkey (SB-cosTR) [Poster no: PO-G-0085]. 44th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition; 25 - 28 May 2011; Sorrento, Italy
26. Dinleyici EC, Eren M, Dogan N, et al. Clinical efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with Blastocystis hominis infection. Parasitol Res 2011;108:541-5
27. Kelesidis T, Pothoulakis C. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therap Adv Gastroenterol 2012;5:111-25
28. Czerucka D, Piche T, Rampal P. Review article: yeast as probiotics - Saccharomyces boulardii. Aliment Pharmacol Ther 2007;26:767-78
29. Czerucka D, Rampal P. Experimental effects of Saccharomyces boulardii on diarrheal pathogens. Microbes Infect 2002;4:733-9
30. Rigothier MC, Maccario J, Gayral P. Inhibitory activity of saccharomyces yeasts on the adhesion of Entamoeba histolytica trophozoites to human erythrocytes in vitro. Parasitol Res 1994;80:10-15
31. Guarino A, Albano F, Ashkenazi S, ESPGHAN/ESPID Evidence-Based Guidelines for the Management of Acute Gastroenteritis in Children in Europe Expert Working Group. European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: executive summary. J Pediatr Gastroenterol Nutr 2008;46(5):619-21.
32. McFarland LV. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol 2008;3:563-78
33. Turck D, Bernet JP, Marx J, et al. Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr 2003;37:22-6
34. Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2005;21:583-90
35. Erdeve O, Tiras U, Dallar Y. The probiotic effect of Saccharomyces boulardii in a pediatric age group. J Trop Pediatr 2004;50:234-6
36. Shan LS, Hou P, Wang ZJ, et al. Prevention and treatment of diarrhoea with Saccharomyces boulardii in children with acute lower respiratory tract infections. Benef Microbes 2013;4:329-34.
37. McFarland LV, Surawicz CM, Greenberg RN, et al. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995;90:439-48
38. Surawicz CM, Elmer GW, Speelman P, et al. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 1989;96:981-8
39. Duman DG, Bor S, Ozütemiz O, et al. Efficacy and safety of Saccharomyces boulardii in prevention of antibioticassociated diarrhoea due to Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 2005;17:1357-61
40. Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a paralel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002;97:2744-9
41. Cindoruk M, Erkan G, Karakan T, et al. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebocontrolled double-blind study. Helicobacter 2007;12:309-16
42. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271:1913-18
43. Klein SM, Elmer GW, McFarland LV, et al. Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers. Pharm Res 1993;10:1615-19
44. Castagliuolo I, Riegler MF, Valenick L, et al. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 1999;67:302-7
45. Saint Marc T, Rossello-Prats L, Touraine JL. Eficacité de Saccharomyces boulardii dans le traitement des diarrhé es du SIDA. Ann Med Interne (Paris) 1991;142:64-5
46. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010;32:1069-79
47. Hurduc V, Plesca D, Dragomir D, et al. A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children. Acta Paediatr 2009;98:127-31
48. Song MJ, Park DI, Park JH, et al. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Helicobacter 2010;15:206-13
49. Ozdil K, Calhan T, Sahin A, et al. Levofloxacin based sequential and triple therapy compared with standard plus probiotic combination for Helicobacter pylori eradication. Hepatogastroenterology 2011;58:1148-52
50. Vandenplas Y, Brunser O, Szajewska H. Saccharomyces boulardii in childhood. Eur J Pediatr 2009;168:253-65
51. Kollaritsch H, Holst H, Grobara P, et al. Prevention of traveler's diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study. Fortschr Med 1993;111:152-6
52. Plein K, Hotz J. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea - a pilot study. Z Gastroenterol 1993;31:129-34
53. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000;45:1462-4
54. Garcia Vilela E, De Lourdes De Abreu Ferrari M, Oswaldo Da Gama Torres H, et al. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scand J Gastroenterol 2008;43:842-8
55. Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2006(4):CD004826
56. Thomas S, Metzke D, Schmitz J, et al. Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis. Am J Physiol Gastrointest Liver Physiol 2011;301:G1083-92
57. Bourreille A, Cadiot G, Le Dreau G, et al. FLORABEST Study Group. Saccharomyces boulardii does not prevent relapse of Crohn's disease. Clin Gastroenterol Hepatol 2013;11:982-7
58. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003;15:697-8
59. Costalos C, Skouteri V, Gounaris A, et al. Enteral feeding of premature infants cwith Saccharomyces boulardii. Early Hum Dev 2003;74:89-96
60. Serce O, Benzer D, Gursoy T, et al. Efficacy of Saccharomyces boulardii on necrotizing enterocolitis or sepsis in very low birth weight infants: a randomised controlled trial. Early Hum Dev 2013;89:1033-6
61. Demirel G, Erdeve O, Celik IH, Dilmen U. Saccharomyces boulardii for prevention of necrotizing enterocolitis in preterm infants: a randomized, controlled study. Acta Paediatr 2013. doi: 10.1111/apa.12416
62. Demirel G, Celik IH, Erdeve O, Dilmen U. Impact of probiotics on the course of indirect hyperbilirubinemia and phototherapy duration in very low birth weight infants. J Matern Fetal Neonatal Med 2013;26:215-18
63. Serce O, Gursoy T, Ovali F, Karatekin G. Effects of Saccharomyces boulardii on Neonatal Hyperbilirubinemia: a randomized controlled trial. Am J Perinatol 2014. [Epub ahead of print]
64. Demirel G, Celik IH, Erdeve O, et al. Prophylactic Saccharomyces boulardii versus nystatin for the prevention of fungal colonization and invasive fungal infection in premature infants. Eur J Pediatr 2013;172:1321-6
65. Maupas JL, Champemont P, Delforge M. Treatment of irritable bowel syndrome with Saccharomyces boulardii: a double-blind, placebo-controlled study. Med Chir Dig 1983;12:77-9
66. Bafutto M, Almeida JR, Leite NV, et al. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii. Arq Gastroenterol 2013;50:304-9
67. Kabir MA, Ishaque SM, Ali MS, et al. Role of Saccharomyces boulardii in diarrhea predominant irritable bowel syndrome. Mymensingh Med J 2011;20:397-401
68. Choi CH, Jo SY, Park HJ, et al. A randomized, double-blind, placebocontrolled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol 2011;45:679-83
69. Floch MH, Walker WA, Madsen K, et al. Recommendations for probiotic use-2011 update. J Clin Gastroenterol 2011;45(Suppl):S168-71
70. Guarner F, Khan AG, Garisch J, et al. World Gastroenterology Organization. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. J Clin Gastroenterol 2012;46:468-81
71. Hill C, Guarner F, Reid G, et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014;doi: 10.1038/nrgastro.2014.66
72. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000;31:1012-17